相似文献
1
The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.时间贴现对克服抗生素市场失灵的经济激励的关键影响。
Nat Rev Drug Discov. 2012 Feb 1;11(2):168. doi: 10.1038/nrd3560-c1.
2
What are the economic barriers of antibiotic R&D and how can we overcome them?抗生素研发的经济障碍有哪些，我们如何克服这些障碍？
Expert Opin Drug Discov. 2018 Oct;13(10):889-892. doi: 10.1080/17460441.2018.1515908. Epub 2018 Sep 1.
3
Antibacterial R&D incentives.抗菌研发激励措施。
Nat Rev Drug Discov. 2011 Sep 30;10(10):727-8. doi: 10.1038/nrd3560.
4
Fix the antibiotics pipeline.修复抗生素研发流程。
Nature. 2011 Apr 7;472(7341):32. doi: 10.1038/472032a.
5
Drug development: Time for teamwork.药物研发：团队合作的时机。
Nature. 2014 May 1;509(7498):S4-5. doi: 10.1038/509S4a.
6
Is the GAIN Act a turning point in new antibiotic discovery?GAIN 法案是否成为新抗生素发现的转折点？
Can J Microbiol. 2013 Mar;59(3):153-6. doi: 10.1139/cjm-2013-0089. Epub 2013 Feb 6.
7
The drug-resistant bacteria that pose the greatest health threats.构成最大健康威胁的耐药细菌。
Nature. 2017 Feb 28;543(7643):15. doi: 10.1038/nature.2017.21550.
8
The drug push.毒品贩卖
Science. 2015 May 22;348(6237):850-3. doi: 10.1126/science.348.6237.850.
9
Market watch: Biopharma deal-making in 2014: a record year for M&A value.市场观察：2014年生物制药交易：并购价值创纪录的一年。
Nat Rev Drug Discov. 2015 Feb;14(2):84-5. doi: 10.1038/nrd4536.
10
Antibiotics in late clinical development.处于后期临床开发阶段的抗生素。
Biochem Pharmacol. 2017 Jun 1;133:152-163. doi: 10.1016/j.bcp.2016.09.025. Epub 2016 Sep 26.
引用本文的文献
1
Sustainable solutions to the continuous threat of antimicrobial resistance.应对抗菌素耐药性持续威胁的可持续解决方案。
Health Aff Sch. 2025 Jan 24;3(2):qxaf012. doi: 10.1093/haschl/qxaf012. eCollection 2025 Feb.
2
The economics of antimicrobial resistance in veterinary medicine: Optimizing societal benefits through mesoeconomic approaches from public and private perspectives.兽医学中抗菌药物耐药性的经济学：从公共和私人角度通过中观经济方法优化社会效益。
One Health. 2020 Jun 5;10:100145. doi: 10.1016/j.onehlt.2020.100145. eCollection 2020 Dec.
3
Bulgecin A as a β-lactam enhancer for carbapenem-resistant and carbapenem-resistant clinical isolates containing various resistance mechanisms.Bulgecin A作为一种β-内酰胺增强剂，用于含有各种耐药机制的耐碳青霉烯临床分离株。
Drug Des Devel Ther. 2016 Sep 20;10:3013-3020. doi: 10.2147/DDDT.S110193. eCollection 2016.
4
β-Lactam Antibiotics Renaissance.β-内酰胺类抗生素的复兴。
Antibiotics (Basel). 2014 May 9;3(2):193-215. doi: 10.3390/antibiotics3020193.
5
A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics.新型抗生素发现与开发激励策略的系统评价与批判性评估
J Antibiot (Tokyo). 2016 Feb;69(2):73-88. doi: 10.1038/ja.2015.98. Epub 2015 Oct 14.
6
Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals.新型抗菌药物临床开发面临的挑战与解决方案：制药行业专业人士的调查结果
Antimicrob Agents Chemother. 2015 Jul;59(7):3695-9. doi: 10.1128/AAC.00638-15. Epub 2015 Apr 27.
7
Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.满足社会对新型抗生素的需求：制药行业面临的挑战。
Br J Clin Pharmacol. 2015 Feb;79(2):168-72. doi: 10.1111/bcp.12401.
8
Novel approaches are needed to develop tomorrow's antibacterial therapies.需要新的方法来开发未来的抗菌疗法。
Am J Respir Crit Care Med. 2015 Jan 15;191(2):135-40. doi: 10.1164/rccm.201410-1894OE.
9
The future of antibiotics.抗生素的未来。
Crit Care. 2014 Jun 27;18(3):228. doi: 10.1186/cc13948.
10
The evolution of the regulatory framework for antibacterial agents.抗菌药物监管框架的演变
Ann N Y Acad Sci. 2014 Sep;1323(1):11-21. doi: 10.1111/nyas.12441. Epub 2014 May 2.
本文引用的文献
1
Antibacterial R&D incentives.抗菌研发激励措施。
Nat Rev Drug Discov. 2011 Sep 30;10(10):727-8. doi: 10.1038/nrd3560.
2
Combating antimicrobial resistance: policy recommendations to save lives.抗击抗菌素耐药性：拯救生命的政策建议。
Clin Infect Dis. 2011 May;52 Suppl 5(Suppl 5):S397-428. doi: 10.1093/cid/cir153.
3
Discounting and decision making in the economic evaluation of health-care technologies.医疗保健技术经济评估中的折扣和决策。
Health Econ. 2011 Jan;20(1):2-15. doi: 10.1002/hec.1612. Epub 2010 May 12.
4
How to improve R&D productivity: the pharmaceutical industry's grand challenge.如何提高研发生产力：制药行业的重大挑战。
Nat Rev Drug Discov. 2010 Mar;9(3):203-14. doi: 10.1038/nrd3078. Epub 2010 Feb 19.
5
Discounting health effects in pharmacoeconomic evaluations: current controversies.药物经济学评价中对健康影响的贴现：当前争议
Pharmacoeconomics. 2005;23(7):639-49. doi: 10.2165/00019053-200523070-00001.
6
The price of innovation: new estimates of drug development costs.创新的代价：药物研发成本的新估计
J Health Econ. 2003 Mar;22(2):151-85. doi: 10.1016/S0167-6296(02)00126-1.
7
Putting a price on biotechnology.为生物技术定价。
Nat Biotechnol. 2001 Sep;19(9):813-7. doi: 10.1038/nbt0901-813.
8
Quantifying the dream: valuation approaches in biotechnology.
Nat Biotechnol. 1998 May;16 Suppl:55-6. doi: 10.1038/5431.
Zotero 插件